Advertisement
Screener

Rapport Therapeutics, Inc. (RAPP) Authorized Dilution

Rapport Therapeutics, Inc. Authorized Dilution

Share-issuance capacity and approved equity plans, with the disclosed share class, period, approval and expiry. Gross charter headroom is authorized minus issued shares, not a forecast. Equity plan reserves may use weighted counting rules, overlap charter capacity, and must not be added to it. Outstanding awards, future grants, and proposed approvals are distinct. * denotes calculated capacity.

As ofAuthorization / planShare classAuthorized / approved limit (shares)Issued shares / outstanding awards (shares)Remaining capacity (shares / reserve units)Approval statusApproval dateExpiry / conditionsBasis / limitationsSource

Similar stocks

Stock NameCountryMarket CapPE Ratio
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Innoviva, Inc. (INVA)United States$1.493B4.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Xencor Inc (XNCR)United States$1.776B-7.33
Septerna, Inc. (SEPN)United States$1.783B-63.01